Graph AI: Innovating Pharmacovigilance and Patient Safety Solutions

Graph AI, a pioneering firm in life sciences technology devoted to pharmacovigilance and patient safety, has successfully secured $3 million in a seed funding round led by Bessemer Venture Partners. The funds will be allocated to bolster the engineering team, expedite product development, and expand its global enterprise customer portfolio.

Established in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, Graph AI is active in the $8 billion pharmacovigilance sector. This regulatory process aims to help pharmaceutical firms monitor and report adverse drug events (ADEs) throughout a drug’s lifecycle. Currently, many pharmaceutical companies depend heavily on manual data extraction and analysis from various unstructured sources, including medical reports, call transcripts, legal documents, and academic literature.

Automating Pharmacovigilance with Graph AI’s Technology

Graph AI’s leading platform, Graph Safety, revolutionises these procedures by employing AI and intelligent automation. The platform streamlines ADE case processing, signal detection, aggregate reporting, and compliance, significantly diminishing the necessity for human intervention to only those regulatory steps that are absolutely required.

This innovative system centralises safety data and enhances accuracy in medical evaluations while ensuring audit preparedness. Clients utilizing Graph AI’s platform have reported marked improvements in efficiency and quicker compliance cycles.

A Skilled Team Driving Growth

The team at Graph AI comprises seasoned professionals with backgrounds in major companies such as Infosys, LTI Mindtree, ServiceNow, Google, and Cisco. With plans to build upon early customer traction across a pipeline of over 7,000 marketed drugs, Graph AI is positioned to scale its operations effectively.